Trials / Unknown
UnknownNCT04306887
A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)
A Open-label, Single-arm Phase Ⅱ Clinical Trial of TQ-B3101 in Subjects With Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 10 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate efficacy and safety of TQ-B3101 in subjects with relapsed/refractory anaplastic large cell lymphoma (ALCL) .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3101 capsule | Escalating doses starting at 200 mg bid. |
Timeline
- Start date
- 2019-11-29
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2020-03-13
- Last updated
- 2020-03-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04306887. Inclusion in this directory is not an endorsement.